BENIGN HEMATOLOGY PROGRAM

Thrombocytic Disorders Clinical Research

 

1. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019 Oct;20(10):e566-e581. doi: 10.1016/S1470-2045(19)30336-5. Epub 2019 Sep 3. PMID: 31492632.

2. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7. PMID: 35772465; PMCID: PMC9236567.

3. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, Larsen AK, Elalamy I; COMPASS–CAT Working Group. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017 Oct;22(10):1222-1231. doi: 10.1634/theoncologist.2016-0414. Epub 2017 May 26. PMID: 28550032; PMCID: PMC5634762.

4. Taher AT, Cappellini MD, Bou-Fakhredin R, Coriu D, Musallam KM. Hypercoagulability and Vascular Disease. Hematol Oncol Clin North Am. 2018 Apr;32(2):237-245. doi: 10.1016/j.hoc.2017.11.001. Epub 2017 Dec 1. PMID: 29458729.

5. El Hasbani G, Taher AT, Jawad A, Uthman I. COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association? Clin Med Insights Arthritis Musculoskelet Disord. 2020 Dec 3;13:1179544120978667. doi: 10.1177/1179544120978667. PMID: 33328777; PMCID: PMC7720319.

6. El Hasbani G, Taher AT, Sciascia S, Uthman I. Antiphospholipid syndrome: the need for new international classification criteria. Expert Rev Clin Immunol. 2021 Apr;17(4):385-394. doi: 10.1080/1744666X.2021.1900733. Epub 2021 Mar 17. PMID: 33682558.

7. Hamadi R, Marlow CF, Nassereddine S, Taher A, Finianos A. Bariatric venous thromboembolism prophylaxis: an update on the literature. Expert Rev Hematol. 2019 Sep;12(9):763-771. doi: 10.1080/17474086.2019.1634542. Epub 2019 Aug 5. PMID: 31219356.

8. El Hasbani G, Saliba AN, Uthman I, Taher AT. Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis. Blood Rev. 2022 Sep 16:101015. doi: 10.1016/j.blre.2022.101015. Epub ahead of print. PMID: 36175215.

9. Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev. 2008 Jul;22(4):187-94. doi: 10.1016/j.blre.2008.03.005. Epub 2008 Apr 15. PMID: 18417261.

10. Hasbani GE, Taher AT, Sunji N, Sciascia S, Uthman I. Antiphospholipid antibodies and cerebrovascular thrombosis in the pediatric population: Few answers to many questions. Lupus. 2021 Aug;30(9):1365-1377. doi: 10.1177/09612033211021488. Epub 2021 Jun 4. PMID: 34082580.

11. Prandoni P, Temraz S, Barbar S, Pesavento R, Taher A. The value of inhibitors of factor Xa for the treatment of pulmonary embolism. Intern Emerg Med. 2014 Sep;9(6):617-22. doi: 10.1007/s11739-014-1085-4. Epub 2014 May 29. PMID: 24871638.

12. Matta BN, Uthman I, Taher AT, Khamashta MA. The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus. Expert Rev Clin Immunol. 2013 Jul;9(7):659-68. doi: 10.1586/1744666X.2013.811183. PMID: 23899236.

13. Abdel-Razeq H, Finianos A, Taher AT. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients. Expert Rev Hematol. 2018 Jun;11(6):487-494. doi: 10.1080/17474086.2018.1480363. Epub 2018 Jun 1. PMID: 29791257.

14. Prandoni P, Temraz S, Taher A. Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials. Semin Hematol. 2014 Apr;51(2):121-30. doi: 10.1053/j.seminhematol.2014.03.006. Epub 2014 Mar 29. PMID: 24861796.

15. Atoui A, Jarrah K, Al Mahmasani L, Bou-Fakhredin R, Taher AT. Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination. Ann Hematol. 2022 May;101(5):1111-1113. doi: 10.1007/s00277-021-04743-1. Epub 2022 Jan 27. PMID: 35083524; PMCID: PMC8791702.

16. Uthman I, Shamseddine A, Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci. 2005 Aug;33(1):11-7. doi: 10.1016/j.transci.2004.10.025. PMID: 15951243.

17. El Hasbani G, Viola M, Sciascia S, Taher AT, Uthman I. Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence. Rheumatol Ther. 2021 Mar;8(1):81-94. doi: 10.1007/s40744-020-00273-w. Epub 2021 Jan 9. PMID: 33420626; PMCID: PMC7991011.

18. Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res. 2009 Mar;123(5):679-86. doi: 10.1016/j.thromres.2008.09.008. Epub 2008 Nov 6. PMID: 18992924.

19. Temraz S, Moukalled N, Gerotziafas GT, Elalamy I, Jara-Palomares L, Charafeddine M, Taher A. Association between Radiotherapy and Risk of Cancer Associated Venous Thromboembolism: A Sub-Analysis of the COMPASS-CAT Study. Cancers (Basel). 2021 Mar 2;13(5):1033. doi: 10.3390/cancers13051033. PMID: 33801174; PMCID: PMC7957620.

20. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost. 2007 Jun;97(6):1031-6. PMID: 17549307.

21. Gerotziafas GT, Mahé I, Lefkou E, AboElnazar E, Abdel-Razeq H, Taher A, Antic D, Elalamy I, Syrigos K, Van Dreden P. Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer. Thromb Res. 2020 Jul;191 Suppl 1:S50-S57. doi: 10.1016/S0049-3848(20)30397-2. PMID: 32736779.

22. Temraz S, Tamim H, Mailhac A, Nassar F, Moukalled N, Jamali F, Taher A. Could Preoperative Unintended Weight Loss Predispose to Postoperative Thrombosis in Patients Undergoing Colorectal Cancer Surgery? An Analysis of the NSQIP Data. J Am Coll Nutr. 2021 Feb;40(2):141-147. doi: 10.1080/07315724.2020.1747031. Epub 2020 Apr 7. PMID: 32255404.

23. Arnaout S, Samaha HR, Succar J, Bou-Akl I, Musallam KM, Taher AT. Antithrombotic prophylaxis in the middle East. Mediterr J Hematol Infect Dis. 2011;3(1):e2011023. doi: 10.4084/MJHID.2011.023. Epub 2011 May 24. PMID: 21713074; PMCID: PMC3113275.

24. Musallam KM, Uthman I, Taher AT. Antiphospholipid syndrome, microalbuminuria, and risk of venous thromboembolism. JAMA. 2009 Sep 2;302(9):945; author reply 945-6. doi: 10.1001/jama.2009.1240. PMID: 19724040.

25. Nassar AH, Musallam KM, Cappellini MD, Taher AT. Pregnancy and risk of venous thromboembolism in developing countries. Br J Haematol. 2009 Sep;146(6):691-2. doi: 10.1111/j.1365-2141.2009.07817.x. Epub 2009 Jul 20. PMID: 19622093.

26. Musallam KM, Taher AT, Haddad MC, Khalil IM. Mondor’s disease of the breast in the context of inherited thrombophilia. Breast J. 2012 Jul-Aug;18(4):373-4. doi: 10.1111/j.1524-4741.2012.01257.x. PMID: 22759096.

27. Taher AT, Aoun J, Salameh P. The AVAIL ME study: a multinational survey of VTE risk and prophylaxis. J Thromb Thrombolysis. 2011 Jan;31(1):47-56. doi: 10.1007/s11239-010-0492-2. PMID: 20549305.

28. Temraz S, Tamim H, Mailhac A, Taher A. Could sodium imbalances predispose to postoperative venous thromboembolism? An analysis of the NSQIP database. Thromb J. 2018 Jul 3;16:11. doi: 10.1186/s12959-018-0165-5. PMID: 29988709; PMCID: PMC6029156.

29. Aoun EG, Musallam KM, Abou-Ghazal M, Taher AT. Malignancy and hypercoagulability: a two-way association revisited. J Thromb Thrombolysis. 2010 Oct;30(3):340-1. doi: 10.1007/s11239-010-0458-4. PMID: 20174855.

30. Aoun EG, Musallam KM, Abou-Ghazal M, Taher AT. Malignancy and hypercoagulability: a two-way association revisited. J Thromb Thrombolysis. 2010 Oct;30(3):340-1. doi: 10.1007/s11239-010-0458-4. PMID: 20174855.

31. Prandoni P, Taher A. Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial). Expert Opin Pharmacother. 2010 Apr;11(6):1035-7. doi: 10.1517/14656561003674397. PMID: 20307227.

32. Bazzi L, Taher AT, Musallam KM, Saleh Z, Masrouha KZ, Uthman I. Thrombotic renal and adrenal manifestations of primary antiphospholipid syndrome. Rheumatol Int. 2010 May;30(7):993-4. doi: 10.1007/s00296-009-1105-2. Epub 2009 Aug 22. PMID: 19701636.

33. Otrock ZK, Taher AT, Shamseddeen WA, Mahfouz RA. Thrombophilic risk factors among 16 Lebanese patients with cerebral venous and sinus thrombosis. J Thromb Thrombolysis. 2008 Aug;26(1):41-3. doi: 10.1007/s11239-007-0093-x. Epub 2007 Sep 6. PMID: 17823778.

34. Shammaa DM, Sabbagh AS, Taher AT, Zaatari GS, Mahfouz RA. Plasminogen Activator Inhibitor-1 (PAI-1) gene 4G/5G alleles frequency distribution in the Lebanese population. Mol Biol Rep. 2008 Sep;35(3):453-7. doi: 10.1007/s11033-007-9106-2. Epub 2007 Jun 20. PMID: 17578681.

35. Nassar H, Zaghal A, Taher A, Mafouz R, Safadi B, Kanso M, Khalife M, Faraj W. Triple thrombophilic simultaneous mutations in patients after bariatric surgery: is there a role for screening in the Eastern Mediterranean? J Surg Case Rep. 2018 Jun 15;2018(6):rjy135. doi: 10.1093/jscr/rjy135. Erratum in: J Surg Case Rep. 2018 Jul 09;2018(7):rjy179. PMID: 29942483; PMCID: PMC6007279.

36. Kantar RS, Haddad AG, Tamim H, Jamali F, Taher AT. Venous thromboembolism and preoperative steroid use: analysis of the NSQIP database to evaluate risk in surgical patients. Eur J Intern Med. 2015 Sep;26(7):528-33. doi: 10.1016/j.ejim.2015.06.005. Epub 2015 Jul 3. PMID: 26148433.

37. Prandoni P, Musallam KM, Taher AT. Predicting venous thromboembolism in hospitalized medical patients: are we there yet? Expert Rev Hematol. 2011 Feb;4(1):1-3. doi: 10.1586/ehm.10.82. PMID: 21322772.

38. Musallam KM, Aoun EG, Mahfouz RA, Khalife M, Taher AT. JAK2V617F and prothrombin G20210A gene mutations in a patient with Budd-Chiari syndrome and essential thrombocythemia. Clin Appl Thromb Hemost. 2010 Aug;16(4):472-4. doi: 10.1177/1076029609332110. Epub 2009 Feb 16. PMID: 19223280.

39. Otrock ZK, Taher AT, Shamseddeen WA, Zaatari G, Bazarbachi A, Mahfouz RA. Factor V HR2 haplotype: a risk factor for venous thromboembolism in individuals with absence of Factor V Leiden. Ann Hematol. 2008 Dec;87(12):1013-6. doi: 10.1007/s00277-008-0543-3. Epub 2008 Jul 25. PMID: 18654780.

40. Kanaan ZM, Mahfouz R, Taher A, Sawaya RA. Bilateral transverse sinus thrombosis secondary to a homozygous C677T MTHFR gene mutation. Genet Test. 2008 Sep;12(3):363-5. doi: 10.1089/gte.2007.0125. PMID: 18666857.

41. Aoun EG, Musallam KM, Uthman I, Beydoun A, El-Hajj T, Taher AT. Childhood stroke in a child with familial Mediterranean fever carrying several prothrombotic risk factors. Lupus. 2009 Aug;18(9):845-7. doi: 10.1177/0961203309103057. PMID: 19578111.

42. Bashshur ZF, Taher A, Masri AF, Najjar D, Arayssi TK, Noureddin BN. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. Retina. 2003 Aug;23(4):486-90. doi: 10.1097/00006982-200308000-00007. PMID: 12972759.

43. Taher AT, Mahfouz RA, Otrock ZK, Rebeiz AG, Sawaya JI. Acute myocardial infarction in a young man: a consequence of inherited thrombophilia and marijuana smoking. Thromb Haemost. 2006 Jun;95(6):1044. doi: 10.1160/TH06-03-0169. PMID: 16732390.

44. Masroujeh R, Shamseddeen W, Isma’eel H, Otrock ZK, Khalil IM, Taher A. Underutilization of venous thromboemoblism prophylaxis in medical patients in a tertiary care center. J Thromb Thrombolysis. 2008 Oct;26(2):138-41. doi: 10.1007/s11239-007-0084-y. Epub 2007 Aug 15. PMID: 17701104.

45. Charafeddine KM, Mahfouz RA, Ibrahim GY, Taher AT, Hoballah JJ, Taha AM. Massive pulmonary embolism associated with Factor V Leiden, prothrombin, and methylenetetrahydrofolate reductase gene mutations in a young patient on oral contraceptive pills: a case report. Clin Appl Thromb Hemost. 2010 Oct;16(5):594-8. doi: 10.1177/1076029609334629. Epub 2009 Jun 10. PMID: 19520679.

46. Uthman I, Khalil I, Sawaya R, Taher A. Lupus anticoagulant, factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis. Clin Rheumatol. 2004 Aug;23(4):362-3. doi: 10.1007/s10067-004-0893-8. Epub 2004 Apr 14. PMID: 15293102.

47. Uthman I, Otrock Z, Taher A. Deep venous thrombosis in a patient with Behçet’s disease and homozygous prothrombin (factor II) G20210A mutation on oral contraceptive pills. Rheumatol Int. 2006 Jun;26(8):758-9. doi: 10.1007/s00296-005-0048-5. Epub 2005 Sep 28. PMID: 16189654.

48. Isma’eel H, Taher A, Alam S, Arnaout MS. Massive pulmonary embolism in a Lebanese patient doubly heterozygous for MTHFR and Factor V Leiden presenting with syncope and treated with tenecteplase. J Thromb Thrombolysis. 2006 Apr;21(2):179-84. doi: 10.1007/s11239-006-4663-0. PMID: 16622615.

49. Shammaa DM, Sabbagh AS, Taher AT, Zaatari GS, Mahfouz RA. Frequency distribution of the G/A alleles of the beta-fibrinogen gene in the Lebanese population. Mol Biol Rep. 2008 Sep;35(3):307-11. doi: 10.1007/s11033-007-9087-1. Epub 2007 May 12. PMID: 17497226.

50. Barada KA, Azar CR, Otrock ZK, Taher AT. Budd-Chiari syndrome with underlying homozygous factor V Leiden and heterozygous methylenetetrahydrofolate reductase mutations. J Gastroenterol. 2005 Oct;40(10):1002-3. doi: 10.1007/s00535-005-1664-2. PMID: 16261441.

51. Jabbour R, Taher A, Shamseddine A, Atweh SF. Moyamoya syndrome with intraventricular hemorrhage in an adult with factor V Leiden mutation. Arch Neurol. 2005 Jul;62(7):1144-6. doi: 10.1001/archneur.62.7.1144. PMID: 16009774.

52. Nassar H, Zaghal A, Taher A, Mahfouz R, Safadi B, Kanso M, Khalife M, Faraj W. Erratum: Triple thrombophilic simultaneous mutations in patients after bariatric surgery: is there a role for screening in the Eastern Mediterranean? J Surg Case Rep. 2018 Jul 9;2018(7):rjy179. doi: 10.1093/jscr/rjy179. Erratum for: J Surg Case Rep. 2018 Jun 15;2018(6):rjy135. PMID: 30002807; PMCID: PMC6037088.

53. Uthman I, Taher A, Khalil I, Bizri AR, Gharavi AE. Catastrophic antiphospholipid syndrome associated with typhoid fever: comment on the article by Hayem et al. Arthritis Rheum. 2002 Mar;46(3):850. doi: 10.1002/art.10086. PMID: 11920434.

54. Taher AT, Musallam KM, Khalil IM. Thromboangiitis obliterans and the inherited thrombophilias: does an association merit consideration? Blood Coagul Fibrinolysis. 2009 Apr;20(3):223-4. doi: 10.1097/MBC.0b013e32831bec27. PMID: 19300047.

55. Sleiman Zade Asfahani WH, Taher AT, Al Rahawi D, Khalil I. Venous thromboembolism in cancer patients referred to the American University of Beirut-Medical Center secondary to deep vein thrombosis; occurrence and risk factors. J Thromb Thrombolysis. 2005 Dec;20(3):179-82. doi: 10.1007/s11239-005-4048-9. PMID: 16261292.

56. Elhajj II, Salem ZM, Birjawi GA, Taher AT, Soweid AM. Heterozygous prothrombin 20210G/A mutation, associated with hyperhomocysteinemia, and homozygous methylenetetrahydrofolate reductase 677C/T mutation, in a patient with portal and mesenteric venous thrombosis. Hematol J. 2004;5(6):540-2. doi: 10.1038/sj.thj.6200560. PMID: 15570301.

57. Otrock ZK, Sharara AI, Mahfouz RA, Taher AT. Compound heterozygosity for factor V and methylenetetrahydrofolate reductase mutations in a patient with Budd-Chiari syndrome. J Gastroenterol Hepatol. 2006 Apr;21(4):782-3. doi: 10.1111/j.1440-1746.2006.04248.x. PMID: 16677174.

58. Taher A, Khalil I, Abou-Merhi R, Shamseddine A, Bazarbachi A. High prevalence of prothrombin G20210A mutation among patients with deep venous thrombosis in Lebanon. Thromb Haemost. 2003 May;89(5):945-6. PMID: 12719795.